Leadership

Mazur talks about his commitment to drug development and what it takes to succeed in the industry today.

For pharma teams, reaping the talent benefits requires skillful oversight.

In this installment of the Harvard Business School Healthcare Alumni Association (HBSHAA) Q&A series, Michael Wong talks to Robert E. Siegel, lecturer in management at the Stanford Graduate School of Business, about determining the optimal combination of digital and physical assets for an S&P 500’s growth playbook.

Addressing whole employee is as important as treating whole patient.

Questions grow over adding titles to the biopharma C-suite.

It’s time to see how you’re doing with putting words into action.

Alicia H. Munnell, Peter F. Drucker Professor of Management Sciences at Boston College’s Carroll School of Management, talks about building long-term financial health via career sustainability.

Building and maintaining relationships can lead to better decisions.

Carolynn Johnson talks about changing the diversity, equity and includsion trends among the most progressive companies.

How can large pharma improve D&I in its companies?

Soft skills are needed to round out the hard numbers.

Examining the incumbent and imminent workforce.

If not addressed, effects could impact innovation, diversity.

Landmark Bio CEO Ran Zheng talks about the value of collaborating with best-in-class partners.

Using the interview process to ensure high organizational standards.

Dr. Randall N. Hyer, SVP Global Medical Affairs at Moderna, talks about the strategies that have helped the company grow from startup to multi-billion-dollar firm in a decade.

For leaders, shifting mindsets and altering dynamics can help.

Insights from AmerisourceBergen EVP and Chief Strategy Officer, Leslie Donato.

Execution of three-pronged approach to combat short-staffed teams can maximize ROI of hiring efforts.

Seeking opportunities to be more inclusive can help pharma companies gain a deeper understanding of key opinion leader and patient perspectives and build diversity into the entire product journey.

Latino executives share their experiences and insights on the community’s contributions to the life sciences industry.

Along with the industry’s massive effort to tackle the health and social problems exposed by COVID, pharma companies have spent the last year addressing the internal impact of racial inequalities following the murder of George Floyd.

Give your team members opportunities to lead for greater growth.

Harvard Business School Professor Joseph B. Fuller talks about the future prospects for pharma sales forces as they face more restrictions on accessing their target physicians and looming concerns of automation.

Lessons learned from the COVID-19 pandemic can help build companies' talent pools and lead to more agile workforce management.